Journal ArticleDOI
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden
Vasily Isakov,Vladimir Chulanov,D.T. Abdurakhmanov,Eduard Burnevich,Elena Nurmukhametova,Galina Kozhevnikova,Natalya Gankina,Sergey V. Zhuravel,Svetlana Romanova,Robert H. Hyland,Sophia Lu,Evguenia S. Svarovskaia,John McNally,Diana M. Brainard,Vladimir Ivashkin,Vyacheslav Morozov,Igor G. Bakulin,Martin Lagging,K. V. Zhdanov,Ola Weiland +19 more
TLDR
Sofosbuvir/velpatasvir as a pangenotypic treatment for 12 weeks was highly effective in patients from Russia and Sweden infected with HCV genotypes 1, 2, or 3 and safe and well-tolerated.Abstract:
Background: In both Russia and Sweden, the dominant hepatitis C virus (HCV) is genotype 1, but around one-third of patients have genotype 3 infection. For such countries, HCV genotype testing is re...read more
Citations
More filters
Journal ArticleDOI
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Marc G. Ghany,Timothy R. Morgan +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) initiated the hepatitis C virus guidance project (hereafter HCV guidance) in 2013 and disseminates up-to-date, peer-reviewed, unbiased, evidence-based recommendations to aid clinicians making decisions regarding the testing, management, and treatment of HCV infection.
Journal ArticleDOI
Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.
Ezequiel Ridruejo,Federico Piñero,Manuel Mendizabal,Hugo Cheinquer,Fernando Herz Wolff,Margarita Anders,Virginia Reggiardo,Beatriz Ameigeiras,Ana Palazzo,Cristina Alonso,Maria Isabel Schinoni,María Grazia Videla Zuain,Federico Tanno,Sebastián Figueroa,Luisa Santos,Mirta Peralta,Alejandro Soza,Cecilia Vistarini,Raúl Adrover,Nora Fernández,Daniela Perez,Nelia Hernández,Claudio Estepo,Andres Bruno,Valeria Descalzi,Marcela Sixto,Silvia Borzi,Daniel Cocozzella,Alina Zerega,Alexandre de Araujo,Adriana Varón,Marcelo Silva +31 more
TL;DR: In this article, a multivariate logistic regression model was used to identify variables associated with the unachieved sustained virological response (SVR), defined as treatment failure (odds ratios [OR] and 95% confidence intervals [CIs]).
Journal ArticleDOI
Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia.
Vasily Isakov,Charlotte Hedskog,Joel O. Wertheim,Reilly Hostager,Bandita Parhy,Adriano de Bernardi Schneider,Vithika Suri,Hongmei Mo,Natalia Geivandova,Vyacheslav Morozov,Elena Bessonova,Natalya Gankina,K. V. Zhdanov,D.T. Abdurakhmanov,Evguenia S. Svarovskaia +14 more
TL;DR: In this article, a deep sequencing of hepatitis C virus (HCV) NS3, NS5A, and NS5B sequences was performed on plasma HCV samples from 412 DAA-naive patients from Russia.
Journal ArticleDOI
Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways.
Alessandra Mangia,Anthony P. Albanese,Marc Bourlière,Antonio Craxì,Douglas T. Dieterich,Sunil S. Solomon,Kim Vanstraelen,Candido Hernandez,Juan Turnes +8 more
TL;DR: The availability of pangenotypic direct-acting antivirals for treatment of hepatitis C (HCV) has provided an opportunity to simplify patient pathways as discussed by the authors, but despite the move towards simplified treatment algorithms, there remains some complexity in the recommendations for the management of genotype-3 patients with compensated cirrhosis.
References
More filters
Journal ArticleDOI
EASL Recommendations on Treatment of Hepatitis C
Jean-Michel Pawlotsky,Alessio Aghemo,Geoffrey Dusheiko,Xavier Forns,Massimo Puoti,Christophe Sarrazin +5 more
TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.
Journal ArticleDOI
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach,Stefan Zeuzem,Michael Manns,Ibrahim Altraif,Ann-Sofi Duberg,David H. Muljono,Imam Waked,Seyed M Alavian,Mei Hsuan Lee,Francesco Negro,Faisal Abaalkhail,Ahmed Abdou,Maheeba Abdulla,Antoine Abou Rached,Inka Aho,Ulus Salih Akarca,Imad Al Ghazzawi,Saad Al Kaabi,Faryal Al Lawati,Khalid Al Namaani,Youssif Al Serkal,Said A. Al-Busafi,Layla Al-Dabal,Soo Aleman,Abdullah S. Alghamdi,Abdulrahman Aljumah,Hamad Al-Romaihi,Monique Andersson,Vic Arendt,Perttu Arkkila,Abdullah M. Assiri,Oidov Baatarkhuu,Abate Bane,Ziv Ben-Ari,Colm Bergin,Fernando Bessone,Florian Bihl,Abdul Rahman Bizri,M. Blachier,Antonio Javier Blasco,Carlos E Brandão Mello,Philip Bruggmann,Cheryl Brunton,Filipe Calinas,Henry Lik-Yuen Chan,Asad Chaudhry,Hugo Cheinquer,Chien-Jen Chen,Rong-Nan Chien,Moon Seok Choi,Peer Brehm Christensen,Wan-Long Chuang,Vladimir Chulanov,Laura Cisneros,Mette Rye Clausen,Matthew E. Cramp,Antonio Craxì,E. A. Croes,Olav Dalgard,Jorge Daruich,Victor de Ledinghen,Gregory J. Dore,Manal H El-Sayed,Gül Ergör,Gamal Esmat,Chris Estes,Karolin Falconer,Elmoubashar Farag,Maria Lucia Gomes Ferraz,Paulo R. Ferreira,Robert Flisiak,Sona Frankova,Ivane Gamkrelidze,Edward Gane,Javier García-Samaniego,Akram Khan,Ilias Gountas,Adrian Goldis,Magnus Gottfredsson,Jason Grebely,Michael Gschwantler,Mario G. Pessoa,Jessie Gunter,Behzad Hajarizadeh,Omer Hajelssedig,Saeed Hamid,Waseem Hamoudi,Angelos Hatzakis,Sayed Himatt,Harald Hofer,Irena Hrstić,Yee Tak Hui,Béla Hunyady,Ramazan Idilman,Wasim Jafri,Rohani Jahis,Naveed Z. Janjua,Peter Jarcuska,Agita Jeruma,Jon G. Jonasson,Yasser Kamel,Jia-Horng Kao,Sabahattin Kaymakoglu,David Kershenobich,Jawad Khamis,Young Sik Kim,Loreta A. Kondili,Zaher Koutoubi,Mel Krajden,Henrik Krarup,Moon sing Lai,Wim Laleman,Wai-cheung C Lao,Daniel Lavanchy,Pablo Lázaro,Henri Leleu,Olufunmilayo A. Lesi,Laurentius A. Lesmana,Michael Li,Valentina Liakina,Young-Suk Lim,Boris Lukšić,Adam Mahomed,Matti Maimets,Mihály Makara,Abraham O. Malu,Rui Tato Marinho,Paul Marotta,Stefan Mauss,Muhammad S. Memon,Maria C Mendes Correa,Nahum Méndez-Sánchez,Shahin Merat,Ammal M. Metwally,Rosmawati Mohamed,Christophe Moreno,Fadi H. Mourad,Beat Müllhaupt,Kimberly Murphy,Helen Nde,Richard Njouom,Diana Nonković,Suzanne Norris,Solomon Obekpa,Stephen Oguche,S. Olafsson,Marian Oltman,Ogu Omede,CE Omuemu,Ohene Opare-Sem,Anne Øvrehus,Shirley Owusu-Ofori,Tsendsuren S. Oyunsuren,George V. Papatheodoridis,Ken Pasini,Kevork M. Peltekian,Richard Phillips,N. N. Pimenov,Hossein Poustchi,Nishi Prabdial-Sing,Huma Qureshi,Alnoor Ramji,Devin Razavi-Shearer,Kathryn Razavi-Shearer,Berhane Redae,Henk W. Reesink,Ezequiel Ridruejo,Sarah Robbins,Lewis R. Roberts,Stuart K. Roberts,William Rosenberg,Françoise Roudot-Thoraval,Stephen D. Ryder,Rifaat Safadi,Olga Sagalova,Riina Salupere,Faisal M. Sanai,Juan F.Sanchez Avila,Vivek A. Saraswat,Rui Sarmento-Castro,Christoph Sarrazin,Jonathan Schmelzer,Ivan Schréter,Carole Seguin-Devaux,Samir Shah,Ala I. Sharara,Manik Sharma,Anatoly Shevaldin,Gamal Shiha,William Sievert,Mark W. Sonderup,Kyriakos Souliotis,Danute Speiciene,Jan Sperl,Peter Stärkel,Rudolf E. Stauber,Catherine A.M. Stedman,Daniel Struck,Tung-Hung Su,Vana Sypsa,Soek Siam Tan,Junko Tanaka,Alexander J. Thompson,Ieva Tolmane,Krzysztof Tomasiewicz,Jonas Valantinas,Pierre Van Damme,Adriaan J. van der Meer,Ingo van Thiel,Hans Van Vlierberghe,Adriana Vince,Wolfgang Vogel,Heiner Wedemeyer,Nina Weis,Vincent Ws Wong,Cesar Yaghi,Ayman Yosry,Man-Fung Yuen,Evy Yunihastuti,Aasim Yusuf,Eli Zuckerman,Homie Razavi +221 more
TL;DR: The global estimate of viraemic HCV infections is lower than previous estimates, largely due to more recent prevalence estimates in Africa, and increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections.
Journal ArticleDOI
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
TL;DR: The goal of the hepatitis C guidance is to provide upto-date recommendations for HCV care practitioners on the optimal screening, management, and treatment for adults with HCV infection in the United States, using a rigorous review process to evaluate the best available evidence.
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Jordan J. Feld,Ira M. Jacobson,Christophe Hézode,Tarik Asselah,Peter Ruane,Norbert Gruener,Armand Abergel,Alessandra Mangia,Ching-Lung Lai,Henry Lik Yuen Chan,Francesco Mazzotta,Christophe Moreno,Eric M. Yoshida,Stephen D. Shafran,William J. Towner,Tram T. Tran,John McNally,Anu Osinusi,Evguenia S. Svarovskaia,Yanni Zhu,Diana M. Brainard,John G. McHutchison,Kosh Agarwal,Stefan Zeuzem +23 more
TL;DR: Once-daily sofosbuvir-velpatasvir for 12 weeks provided high rates of sustained virologic response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis.
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R. Foster,Nezam H. Afdhal,Stuart K. Roberts,Norbert Bräu,E.J. Gane,S. Pianko,E.J. Lawitz,Alexander J. Thompson,Mitchell L. Shiffman,Curtis L Cooper,William J. Towner,Brian Conway,Peter Ruane,M. Bourliere,Tarik Asselah,Thomas Berg,S. Zeuzem,William Rosenberg,Kosh Agarwal,Catherine A.M. Stedman,Hongmei Mo,Hadas Dvory-Sobol,Lingling Han,Jing Wang,John McNally,Anu Osinusi,Diana M. Brainard,John G. McHutchison,Francesco Mazzotta,Tram T. Tran,Stuart C. Gordon,Keyur Patel,Nancy Reau,Alessandra Mangia,Mark S. Sulkowski +34 more
TL;DR: Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.
Related Papers (5)
Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis
Huiying Rao,Xingxiang Yang,Youwen Tan,Qin Ning,Daokun Yang,Jie-Fei Wang,Yongfeng Yang,Sujun Zheng,Dongliang Yang,Jinlin Hou,Qing Xie,Caiyan Zhao,Lunli Zhang,Xiao-rong Mao,Tong Sun,Lang Bai,Fuchun Zhang,Jinglan Jin,Yingren Zhao,Maorong Wang,Wen Xie,Yingjie Ma,Jun Quan,Xuebing Yan,Ping An,Feng Lin,Jidong Jia,Xiaoxuan Hu,Zuojiong Gong,Jie Wu,Yongping Chen,Zhansheng Jia,Minghua Lin,Guiqiang Wang,Yueyong Zhu,Zhang Yingjun,Hongming Xie,Lin Luo,Ren Qingyun,Rui Huang,Lai Wei +40 more
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection
Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis
M.B. Ferret,Juan A. Pineda,José Luis Calleja Panero,M. Rodríguez,Rosa Maria Morillas,Juan Manuel Pascasio,Antonio Rivero,Brian McNabb,Gulan Zhang,Gregory Camus,L.M. Stamm,D.M. Brainard,Mani Subramanian,José A. Carrión,R.J. Andrade,L.E.M. Amado,Juan Turnes,Sabela Lens,Miguel A. Casado,R. Esteban +19 more